magnetismm-3: elranatamab for myeloma
Published 3 years ago • 498 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
6:07
magnetismm-3: elranatamab in r/r multiple myeloma naive to bcma-directed therapy
-
10:39
magnetismm-3: elranatamab in relapsed/refractory multiple myeloma
-
6:14
ongoing studies of elranatamab in frail patients & with darapomdex: magnetismm-3 & magnetismm-5
-
1:35
indirect comparison of elranatamab in magnetismm-3 versus real-world treatment regimens
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
3:27
patient-reported outcomes with the use of elranatamab in the magnetismm-3 trial
-
6:07
elranatamab for r/r myeloma: long-term updates from magnetismm-3 & real-world safety of this agent
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
4:33
brawm: bendamustine, rituximab and acalabrutinib for waldenström’s macroglobulinemia
-
1:08:23
day 3 - harnessing geometric ml for molecular design | michael bronstein
-
15:43
elranatamab - upcoming myeloma therapy
-
1:37
the promise of elranatamab and other bispecifics in the treatment of myeloma
-
2:47
magnestismm-1: elranatamab alone or with immunomodulatory agents in r/r multiple myeloma
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
3:47
magnetismm-3: correcting hypogammaglobulinemia & using ig replacement therapy to reduce infections
-
1:52
impact of prior bcma-directed therapy on the efficacy of elranatamab in r/r multiple myeloma
-
2:10
magnetismm-4: elranatamab in combination with other agents for patients with multiple myeloma
-
1:16
insights into the magnetismm-4 trial
-
1:46
myeloma: elranatamab mechanism of action
-
6:54
elranatamab: extended follow-up & biweekly admin for rrmm | magnetismm-3 study | asco 2023
-
2:12
magnetismm-1: investigating the efficacy of elranatamab in patients with r/r multiple myeloma
-
9:14
efficacy and safety of elranatamab in pts with relapsed/refractory multiple myeloma: magnetismm-3